Clinical Trials
Study of BMS-986489 vs durvalumab in limited stage small cell lung cancer
Disease Type: Lung
An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville